Abstract
Cardiovascular disease is a major cause of higher mortality of middle-aged and elderly males in comparison to women. Sex hormones action on cardiovascular system is the most likely explanation of this differences. Nevertheless, estradiol and cardiovascular disease relationship is still unclear. The authors conducted a systematic review to identify the association of endogenous estradiol with cardiovascular endpoints in men. Articles were identified by a MedLine search (1961 — July 2023) and citation tracking. No evidence synthesis was conducted. 24 eligible articles were found. In 10 studies no association of sex hormones and endpoints was found. In 7 studies there was an association of testosterone and endpoints, but no significant results for estradiol. 7 studies have reported significant association of estradiol and cardiovascular endpoints. Inconsistency in evidence is significantly influenced by differences between studies in patient age, follow-up, researched endpoints and quality of estradiol essay. Over 40% of published studies, that researched the association of estradiol and death, found such a link. However, existing body of literature is largely heterogenous and doesn’t provide definite evidence for a pronounced net effect of estradiol on cardiovascular health in general men population. The present systematic review hints, that endogenous estradiol could be linked with cardiovascular risks in white men of young and middle age.
Publisher
Paediatrician Publishers LLC
Reference56 articles.
1. Федеральная служба государственной статистики. Женщины и мужчины России 2022: стат. сборник. — М., 2022. — 208 с. [Federalnaya sluzhba gosudarstvennoj statistiki. ZHenshchiny i muzhchiny Rossii 2022: Statisticheskij sbornik. Moscow; 2022. 208 p. (In Russ.)]
2. Association between endogenous sex steroid hormones and inflammatory biomarkers in US men
3. Sex-dependent association of blood pressure with oestrogen receptor genes ER?? and ER??
4. Estrogen effects on osmotic regulation of AVP and fluid balance
5. The Coronary Drug Project